Compare Sanofi SA (SNY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs 10X Genomics Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Sanofi SA is far larger — about 19.1× 10X Genomics Inc's market cap, and Sanofi SA pays a 5.5% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SNY | TXG | |
|---|---|---|
Market Cap | $104.83B | $5.48B |
Sector | Health | Health |
52-Week High | $52.34 | $45.80 |
52-Week Low | $41.33 | $11.34 |
Enterprise Value | $121.32B | $5.02B |
Dividend Yield | 5.5% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
